Phase I Trial of Pyragrel, a Novel Thromboxane Synthetase Inhibitor, to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers

• Main Authors: Chan Zou (Author), Xiaocong Zuo (Author), Jie Huang (Author), Ye Hua (Author), Shuang Yang (Author), Xiaoyan Yang (Author), Can Guo (Author), Hongyi Tan (Author), Jun Chen (Author), Zhaoxing Chu (Author), Qi Pei (Author), Guoping Yang (Author)
• Format: Book
• Published: Frontiers Media S.A., 2019-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background and Objective: Inhibition of thrombosis and platelet aggregation through a thromboxane synthetase inhibitor proved to be an effective and promising treatment for cardiovascular and/or cerebrovascular disease (CCVD) patients. This phase I study evaluated the safety, tolerability, and pharm...